VIVEbiotech
vivebiotech.com
Cell & Gene Therapy
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Ampersand Capital PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
VIVEbiotech Launches Lentiviral Vector Manufacturing Plant for Cell and Gene Therapies Pharmaceutical Technology
VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.
Read more
Report
VIVEbiotech Appoints Patricio Massera as President
Veteran CDMO executive to guide next phase of global expansion and operational excellence for lentiviral vector manufacturer.
Read more
Report
VIVEbiotech Appoints Patricio Massera as President
Veteran CDMO executive to guide next phase of global expansion and operational excellence for lentiviral vector manufacturer. VIVEbiotech VIVEbiotech Patricio Massera Patricio Massera, President, VIVEbiotech San Sebastián, Gipuzkoa, Spain, July 03, 2025 (
Read more
Report
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners ("Ampersand"), a private equity firm specializing in the life sciences and heal
Read more
Report
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
/PRNewswire/ -- VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment...
Read more
Report
Vivebiotech Secures Growth Investment From Ampersand Capital Partners To Expand Lentiviral Vector Development And Manufacturing Capabilities
Vivebiotech Secures Growth Investment From Ampersand Capital Partners To Expand Lentiviral Vector Development And Manufacturing Capabilities. SAN SEBASTIAN, Spain, Dec. 4, 2024 /PRNewswire/ -- VIVEbiotech, a leadinglentiviral vector Contract Development a
Read more
Report
PharmiWeb.com - Thank you
After twenty-five years, PharmiWeb.com is closing. A note of thanks to the pharmaceutical industry community that built it.
Read more
Report
With demand surging for lentiviral vectors, CDMO VIVEbiotech expands capacity 400% in cross-town move
Read more
Report
Whistleblower Software
Leading Whistleblowing System. Reporting & Case Management ISAE 3000 GDPR Compliant E2E-encrypted.
Read more
Report